View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 31, 2017updated 13 Jul 2022 10:08am

Boehringer to study new immunotherapy in Phase I oncology trial

Boehringer Ingelheim has expanded its strategic partnership with research organisation Sarah Cannon Research Institute to investigate BI 891065 in a Phase I clinical trial to treat patients with solid tumours.

Boehringer Ingelheim has expanded its strategic partnership with Sarah Cannon Research Institute to investigate BI 891065 in a Phase I clinical trial to treat patients with solid tumours.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

BI 891065 is a potent small molecule SMAC mimetic being developed to stimulate cell death of tumours and activate immune system to potentially enhance the immunotherapy activity.

The Phase I trial will evaluate BI 891065 as monotherapy and combination therapy with an anti-PD-1 cancer treatment, BI 754091, for advanced metastatic tumours and will enrol around 100 subjects

The interventional, non-randomised, open-label trial will assess the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of BI 891065.

Boehringer Ingelheim Oncology global medical head Mehdi Shahidi said: “We are significantly expanding our efforts in this area, including a broad research programme focusing on the development of rational combinations of novel immuno-oncology approaches.

“The Phase I trial will evaluate BI 891065 as monotherapy and combination therapy with an anti-PD-1 cancer treatment, BI 754091, for advanced metastatic tumours.”

“As part of these ongoing efforts to transform the lives of cancer patients, we are extremely proud to be one of the first companies to bring this innovative combination therapy of an immune checkpoint inhibitor and a small molecule targeted treatment to the clinical stage of development.”

The trial aims to establish a maximum tolerated dose (MTD) and/or recommended dose, while the secondary objectives are pharmacokinetic (PK) profile of BI 891065 alone and when combined with BI 754091, and preliminary assessment of anti-tumour activity.

Under a joint clinical development programme, the firms previously investigated Boehringer’s BI 754091 and BI 754111 monoclonal antibodies for the treatment of various cancers.

The current extension of the partnership is intended to accelerate patient enrolment and expand access to Boehringer’s investigational oncology treatments through Sarah Cannon’s network in the US and UK.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena